NTRA | tickerfilter.com

Fundamental analysis

42%

Profitability 25%

Dept financing 38%

Liquidity 59%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.39%

1 Month

-2.03%

3 Months

-11.57%

6 Months

22.89%

1 Year

67.11%

2 Year

168.46%

Key data

Stock price

$148.08

P/E Ratio

0.00

DAY RANGE

$147.13 - $150.09

EPS

-$2.02

52 WEEK RANGE

$87.20 - $183.00

52 WEEK CHANGE

$67.11

MARKET CAP

20.899 B

YIELD

N/A

SHARES OUTSTANDING

123.681 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.02

PUBLIC FLOAT

AVERAGE 10 VOLUME

$861,003

AVERAGE 30 VOLUME

$1,495,458

Company detail

CEO: Stephen Chapman
Region: US
Website: natera.com
Employees: 3,020
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage.

NTRA - Natera, Inc.